Feb 23, 2022 8:00am EST Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022
Jan 14, 2022 8:00am EST Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cinrebafusp Alfa
Jan 03, 2022 7:00am EST Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402
Nov 08, 2021 8:00am EST Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-344/S095012
Nov 02, 2021 7:00am EDT Pieris Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Oct 26, 2021 8:00am EDT Pieris Pharmaceuticals To Host Third Quarter 2021 Investor Call and Provide Corporate Update on November 2, 2021
Oct 06, 2021 8:00am EDT Pieris Pharmaceuticals Announces Appointments of Chief Financial Officer and Chief Business Officer
Aug 24, 2021 9:00am EDT Pieris Pharmaceuticals Announces PRS-220 Presentation at ERS Highlighting Preclinical Data for CTGF Inhibitor
